At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
BVD-523drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
In Brief
A Phase 2 clinical trial evaluating BVD-523 for Advanced Solid Tumors. Completed, enrolled 136 participants across 9 sites.
Detailed Summary
This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The study also seeks to demonstrate target modulation and early signs of clinical response in select patient populations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartMar 2013
Primary CompletionFeb 2018
Study CompletionSep 2018
TodayJul 2026
First PostedFeb 1, 2013
Enrollment StartMar 1, 2013
Primary CompletionFeb 1, 2018
Study CompletionSep 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.4 years ago
Interventions
BVD-523drug
Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle